Palvella Therapeutics (PVLA) Change in Accured Expenses (2013 - 2026)
Palvella Therapeutics' (PVLA) quarterly Change in Accured Expenses came in at -$900000.0 in Q1 2026, up 69.07% year-on-year from -$532317.1 in Q1 2025, and down 408.22% on a QoQ basis from $292000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 8 years of Change in Accured Expenses data on file, last reported at -$900000.0 in Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 69.07% year-over-year to -$900000.0 in Q1 2026; TTM through Mar 2026 was $710000.0, a 133.08% increase from a year earlier, with the FY2025 full-year figure at -$1.3 million, down 223.81% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$900000.0, down from $292000.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for PVLA reached as high as $801000.0 in Q3 2025 and fell as low as -$2.9 million in Q1 2025.
- Historically, Change in Accured Expenses has averaged -$127777.8 across 3 years, with a median of $292000.0 in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 181.56% in 2025 and fell as far as 1117.48% in 2025.
- Year by year, Change in Accured Expenses stood at -$358000.0 in 2024, then surged by 181.56% to $292000.0 in 2025, then sank by 408.22% to -$900000.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$900000.0 in Q1 2026, $292000.0 in Q4 2025, and $801000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | -16.74 Mn |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.62 Bn | - | -900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -900,000.00 |
| Mar 31, 2026 | -900,000.00 |
| Dec 31, 2025 | 292,000.00 |
| Dec 31, 2025 | 292,000.00 |
| Sep 30, 2025 | 801,000.00 |
| Sep 30, 2025 | 801,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Mar 31, 2025 | -2.91 Mn |
| Mar 31, 2025 | -2.91 Mn |
| Dec 31, 2024 | -358,000.00 |
| Dec 31, 2024 | -358,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Jun 30, 2024 | 739,000.00 |
| Jun 30, 2024 | 739,000.00 |
| Mar 31, 2024 | 286,000.00 |
| Mar 31, 2024 | 286,000.00 |
| Dec 31, 2017 | 1.01 Mn |
| Dec 31, 2017 | 1.01 Mn |